FDA Says Ivermectin Not a COVID Treatment, Warns of Dangers | Local News I Racine County Eye
The United States Food and Drug Administration (FDA) has warned doctors and pharmacists nationwide against the use of the drug ivermectin in the treatment or prevention of COVID-19.
In separate letters to the heads of the Federation of State Medical Boards and the National Association of Pharmacy Boards, Shannon N. Glueck, acting chief of branch 4 of the FDA, wrote that the agency did not has “neither authorized nor approved the use of any drug containing ivermectin. in the prevention or treatment of COVID-19.
Glueck noted that although clinical trials evaluating ivermectin tablets for the treatment of COVID-19 in humans are ongoing, there is currently no data available that shows the drug to be safe or effective for the patient. treatment or prevention of COVID-19.
The letter from the FDA also listed many side effects associated with ivermectin, “including rash, nausea, vomiting, diarrhea, stomach pain, swelling of the face or limbs, dizziness, seizures, sudden drop in blood pressure, severe rash potentially requiring hospitalization, and liver damage (hepatitis). “
Ivermectin has been approved by the FDA for humans “in very specific doses to treat certain parasitic worms” as well as topical formulations (on the skin) for head lice and skin conditions, such as rosacea. The letter says the FDA recently received complaints about the makeup of pharmacies selling pharmaceuticals containing ivermectin and claiming the products can treat or prevent COVID-19.
The Wisconsin Medical Examination Board is a member of the Federation of State Medical Boards. Additionally, members of the National Association of Boards of Pharmacy (NAFB) include the Wisconsin Pharmacy Examining Board.
The Racine County Eye is committed to posting the most recent and accurate information regarding the COVID-19 pandemic in our Coronavirus section. Check out our COVID-19 dashboard which offers real-time statistical reports (updated daily) for Racine County.